Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis

Rheumatology International

Volumn 29, Issue 9, 2009, Pages 1017-1024

  Coral Alvarado, Paola ^a   Quintana, Gerardo ^a   Garces, Maria Fernanda ^a   Cepeda, Libia Alexandra ^a   Caminos, Jorge Eduardo ^a   Rondon, Federico ^a   Iglesias Gamarra, Antonio ^a   Restrepo, Jose Felix ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Biomarkers; Endoglin; Endothelin 1; Hypertension; Scleroderma

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; ENDOTHELIN 1; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS;

ADULT; AGE OF ONSET; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; RECEPTORS, CELL SURFACE; SCLERODERMA, SYSTEMIC;

EID: 67349153806     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0829-8     Document Type: Article

References (50)

1. EC LeRoy C Black R Fleischmajer 1988 Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J Rheumatol 15 202 205 (Pubitemid 18073738)
2. MB Kahaleh 1992 The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy) Clin Exp Rheumatol 10 Suppl 7 51 56
3. JASW Block 2001 Raynaud's phenomenon Lancet 23 20 28
4. AL Herrick 2000 Vascular function in systemic sclerosis Curr Opin Rheumatol 12 527 533 10.1097/00002281-200011000-00009
5. CP Denton CM Black 2003 Pulmonary hypertension in systemic sclerosis Rheum Dis Clin North Am 29 335 349 10.1016/S0889-857X(03)00024-3 (Pubitemid 36765124)
6. JG Coghlan D Mukerjee 2001 The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology Curr Opin Rheumatol 13 495 499 10.1097/00002281-200111000-00008
7. FMLJ Wigley M Mayes D McLain 2005 The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists Arthritis Rheum 52 2125 2132 10.1002/art.21131
8. British Cardiac Society Guidelines 2001 Recommendations on the management of pulmonary hypertension in clinical practice Heart 86 Suppl I1 I13
9. R Vancheeswaran T Magoulas G Efrat 1994 Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 21 1838 1844 (Pubitemid 24312644)
10. AD Cambrey NK Harrison KE Dawes 1994 Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro Am J Respir Cell Mol Biol 11 439 445
11. S Morelli C Ferri L Di Francesco 1995 Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension Ann Rheum Dis 54 730 734
12. S Morelli C Ferri E Polettini 1995 Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis Am J Med 99 255 260 10.1016/S0002-9343(99)80157-0
13. K Yamane T Miyauchi N Suzuki 1992 Significance of plasma endothelin-1 levels in patients with systemic sclerosis J Rheumatol 19 1566 1571
14. MB Kahaleh 1991 Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action Arthritis Rheum 34 978 983 10.1002/art.1780340807
15. NRP Venkatesan MS Ludwing 2002 Proteoglycan expression in bleomycin lung fibroblasts: role of transforming growth factor-beta (1) and interferon-gamma Am J Physiol Lung Cell Mol Physiol 283 L806 L814
16. SP Atamas B White 2003 The role of chemokines in the pathogenesis of scleroderma Curr Opin Rheumatol 15 772 777 10.1097/00002281-200311000-00015
17. J Varga 2002 Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis Arthritis Rheum 46 1703 1713 10.1002/art.10413
18. MC Tamby Y Chanseaud L Guillevin 2003 New insights into the pathogenesis of systemic sclerosis Autoimmun Rev 2 152 157 10.1016/S1568-9972(03)00004-1
19. F Verrecchia A Mauviel D Farge 2006 Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis Autoimmun Rev 5 563 569 10.1016/j.autrev.2006.06.001
20. CP Denton DJ Abraham 2001 Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis Curr Opin Rheumatol 13 505 511 10.1097/00002281-200111000-00010
21. P Sambo SS Baroni M Luchetti 2001 Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway Arthritis Rheum 44 2653 2664 10.1002/1529-0131(200111)44: 11<;2653::AID-ART445>;3.0.CO;2-1 (Pubitemid 33049343)
22. CP Denton CM Black DJ Abraham 2006 Mechanisms and consequences of fibrosis in systemic sclerosis Nat Clin Pract Rheumatol 2 134 144 10.1038/ncprheum0115
23. J Varga D Abraham 2007 Systemic sclerosis: a prototypic multisystem fibrotic disorder J Clin Invest 117 557 567 10.1172/JCI31139
24. MB Bolster A Ludwicka SE Sutherland 1997 Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis Arthritis Rheum 40 743 751 10.1002/art.1780400422
25. T Kadono K Kikuchi H Ihn 1998 Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts J Rheumatol 25 296 301 (Pubitemid 28088258)
26. AE Koch LB Kronfeld-Harrington Z Szekanecz 1993 In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease Pathobiology 61 239 246 (Pubitemid 24007481)
27. RMBJ Strieter MP Keane 2002 CXC chemokines in angiogenesis related to pulmonary fibrosis Chest 122 298S 301S 10.1378/chest.122.6-suppl.298S (Pubitemid 36043017)
28. FJDE Burrows PL Tazzari P Amlot 1995 Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy Clin Cancer Res 1 1623 1634 (Pubitemid 26030991)
29. ECR Torsney D Parums M Collis 2002 Inducible expression of human endoglin during inflammation and wound healing in vivo Inflamm Res 51 464 470 10.1007/PL00012413 (Pubitemid 35034452)
30. SHHL Wong S Chevalier A Philip 2000 Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors Eur J Biochem 267 5550 5560 10.1046/j.1432-1327.2000.01621.x
31. JG Walker J Stirling D Beroukas 2005 Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis Pathology 37 220 225 10.1080/00313020500033262
32. A Leask DJ Abraham DR Finlay 2002 Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts Arthritis Rheum 46 1857 1865 10.1002/art.10333
33. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic, Therapeutic Criteria Committee 1980 Arthritis and Rheum 23 581 590
34. RW Battle MA Davitt SM Cooper 1996 Prevalence of pulmonary hypertension in limited and diffuse scleroderma Chest 110 1515 1519 10.1378/chest.110.6.1515 (Pubitemid 26425153)
35. D Mukerjee D George St B Coleiro 2003 Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach Ann Rheum Dis 62 1088 1093 10.1136/ard.62.11.1088
36. PJ Clements PA Lachenbruch JR Seibold 1993 Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies J Rheumatol 20 1892 1896 (Pubitemid 24031593)
37. A Kuryliszyn-Moskal PA Klimiuk S Sierakowski 2005 Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement Clin Rheumatol 24 111 116 10.1007/s10067-004-0987-3
38. AM Southcott KP Jones D Li 1995 Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis Am J Respir Crit Care Med 151 1604 1612
39. B Crestani N Seta E Palazzo 1994 Interleukin-8 and neutrophils in systemic sclerosis with lung involvement Am J Respir Crit Care Med 150 1363 1367 (Pubitemid 24356653)
40. S Furuse H Fujii Y Kaburagi 2003 Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis J Rheumatol 30 1524 1528 (Pubitemid 36835450)
41. M Hasegawa M Fujimoto K Kikuchi 1997 Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis J Rheumatol 24 663 665 (Pubitemid 27146081)
42. S Majewski A Wojas-Pelc M Malejczyk 1999 Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis Acta Derm Venereol 79 207 210 10.1080/000155599750010986
43. F Meloni R Caporali A Marone Bianco 2004 BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis Sarcoidosis Vasc Diffuse Lung Dis 21 111 118 (Pubitemid 38954751)
44. E Scala S Pallotta A Frezzolini 2004 Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement Clin Exp Immunol 138 516 540 10.1111/j.1365-2249.2004.02642.x
45. MR Hussein HI Hassan ER Hofny 2005 Alterations of mononuclear inflammatory cells, CD4/CD8 + T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis J Clin Pathol 58 178 184 10.1136/jcp.2004. 019224
46. M Fujimoto M Hasegawa Y Hamaguchi 2006 A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease Dermatology 213 88 92 10.1159/000093846
47. N Snowden B Coupes A Herrick 1994 Plasma TGF beta in systemic sclerosis: a cross-sectional study Ann Rheum Dis 53 763 767
48. M Dziadzio RE Smith DJ Abraham 2005 Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score Rheumatology (Oxford) 44 1518 1524 10.1093/rheumatology/kei088
49. A Ludwicka T Ohba M Trojanowska 1995 Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma J Rheumatol 22 1876 1883
50. K Kikuchi T Kadono H Ihn 1995 Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1 J Invest Dermatol 105 128 132 10.1111/1523-1747.ep12313452